Vital Signs Solutions receives backing to facilitate mass-scale antibody testing for COVID-19
.jpg)
The company will adapt its digital platform to digitize any COVID-19 antibody rapid test assay and embed this within an app available on smartphones and tablets.
Vital Signs Solutions, an early-stage, startup developing innovative, digital preventative healthcare solutions, has been awarded a significant grant by Innovate UK as part of the UK Government's support for innovation that can alleviate the effects of the COVID-19 crisis.
The company will adapt its digital platform, called PocDoc, to digitize any COVID-19 antibody rapid test assay and embed this within an app available on smartphones and tablets.
The app will be able to collect additional data to help track and analyse the spread of the virus and its impact on the presence of antibodies in the population.
The first version of the app has been finished and will be undergoing real-world beta testing in the coming weeks.
In addition to its efforts to help tackle COVID-19, Vital Signs Solutions is continuing to develop its own range of physical blood tests that are integrated with its PocDoc platform, with results delivered immediately via the PocDoc app.
Steve Roest, CEO of Vital Signs Solutions, commented: A digital platform is critical to facilitate the scaling of antibody testing and we are confident our PocDoc platform can be adapted to solve this problem."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.